What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report Amgen's unaudited financial results for the first quarter ended March 31, 2020, and to furnish the accompanying press release which contains these detailed financial results and discussions.

Why does Amgen present non-GAAP financial measures?

Amgen believes that presenting non-GAAP financial measures provides useful supplementary information to investors, enhancing their understanding of the company's financial performance and future prospects. These measures facilitate comparisons of ongoing business operations across different periods by excluding items that can distort the view of core operational results.

What is Free Cash Flow (FCF) and why is it important to Amgen?

Free Cash Flow (FCF) is calculated by subtracting capital expenditures from operating cash flow, as determined in accordance with GAAP. Amgen presents FCF as an additional measure of the company's liquidity, indicating the cash generated from operations after accounting for necessary investments in assets.

AMGN 8-K: Earnings & Results

Q: What are the key differences between Amgen's GAAP and non-GAAP financial measures?

Amgen's non-GAAP financial measures exclude certain items from GAAP results to provide a clearer view of ongoing operational performance. These excluded items typically include acquisition-related expenses (like amortization of acquired intangibles), restructuring charges, and certain legal settlement expenses, which are considered by the company to be outside the ordinary course of business or to have inconsistent timing and magnitude.

Summary

Amgen Inc. filed an 8-K on April 30, 2020, to report its unaudited financial results for the first quarter ended March 31, 2020. The filing primarily furnished a press release detailing these results, which included both GAAP and non-GAAP financial measures. Investors should note that Amgen uses non-GAAP measures like non-GAAP earnings per share, operating income, and net income to provide a more enhanced view of its ongoing business operations and facilitate comparisons across periods. The company also highlighted its Free Cash Flow (FCF) as a key liquidity measure. The non-GAAP adjustments primarily exclude acquisition-related expenses (like amortization of acquired intangibles), restructuring charges, and certain legal settlement expenses, which are considered by Amgen to be outside the ordinary course of business or inconsistent in timing and magnitude. These adjustments aim to present a clearer picture of underlying operational performance.

Key Highlights

1Amgen reported its Q1 2020 unaudited financial results on April 30, 2020, via an 8-K filing.
2The company provided both GAAP and non-GAAP financial measures in its earnings release.
3Non-GAAP measures are presented to offer a clearer view of ongoing business operations and facilitate period-over-period comparisons.
4Key non-GAAP adjustments include acquisition-related expenses, restructuring charges, and certain legal settlement expenses.
5Free Cash Flow (FCF) was presented as a measure of liquidity.
6The press release containing the detailed financial results was furnished as an exhibit.
7Information in this 8-K filing is not deemed 'filed' for certain regulatory purposes and is not incorporated by reference into other filings.

AMGEN INC 8-K Report, Financial Results (Apr 30, 2020)

Summary

Key Highlights

Frequently Asked Questions